Speakers Include:

Groundbreaking Advances and Key Opinions within Anti-Infective Drug Discovery and Development

The global anti-infective market is currently estimated at $66.5 billion, with anti-bacterial agents accounting for more than 50% of sales. Many biotechs and pharmaceutical companies are seeing developments in later stage clinical trials, specifically in anti-bacterial and anti-fungal, both of which are growing in demand. The threat of bacterial resistant strains of infectious diseases continually increases and creates a race to develop an effective resistant drug to combat these strains.

The Anti-Infectives Summit will discuss effective lead generation approaches currently being used in anti-bacterial, anti-viral and anti-fungal drug discovery and address which biologics may play a role in anti-infective therapy.

Download a snapshot of our past attending companies

IQPC’s Anti-Infectives Summit will address key areas, including:

  • What will the anti-infectives market look like in 10 to 20 years?
  • The impact of bacterial resistance on drug development
  • Formulating an effective anti-infective drug development pipeline
  • Clinical trial design and results within anti-bacterial/fungal drug resistance & mutant prevention
  • Discovering new antibiotic classes effective against gram-negative organisms
  • Identifying diagnostic technologies that support narrow spectrum drug development and commercialization
  • IDSA/CDC overview of key threats
  • Regulatory landscape and advances with NIAID and other government agencies as collaborators or sources of funding
  • Emerging antibiotic resistance trends, market countries and infectious diseases needs
  • Updates on superbug resistance pipelines combating certain superbug strains
  • Uncovering where the next novel antibacterial leads come from
  • Target vs. cell-based screens - Are novel targets showing any signs of success?

Who should attend?

VPs, Heads, Directors and Managers of:

  • Microbiology
  • Immunology
  • Infectious Diseases
  • Medicinal Chemistry
  • Clinical Pharmacology
  • Drug Discovery
  • New Product Development
  • Scientific Affairs
  • Licensing
  • Antibiotics
  • Infection Discovery
  • Drug evaluation
  • Molecular Biotechnology
  • Drug Development
  • Project Management
  • Preclinical Development
  • Portfolio Management
Sponsors Media Partners
sponsors Media Partners

[ Register Now ]